Evidence for AD-associated GABAergic remodeling along with the failure of anti-glutamatergic and acetylcholinesterase inhibitor therapies to halt the progression of the disease could point to the GABAergic system as a promising therapeutic target for AD. This evidence concerns the gene ACHE and Alzheimer disease.